Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia

Blood

Volumn 101, Issue 8, 2003, Pages 3049-3051

  Hong, Aaron P ^b   Cook, Deborah J ^b   Sigouin, Christopher S ^b   Warkentin, Theodore E ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ARM; ARTICLE; BLOOD VESSEL INJURY; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG INDUCED DISEASE; HUMAN; HYPERCOAGULABILITY; LEG; MAJOR CLINICAL STUDY; MORBIDITY; PRIORITY JOURNAL; THROMBOCYTOPENIA; AUTOIMMUNE DISEASE; CANADA; CASE CONTROL STUDY; CENTRAL VENOUS CATHETERIZATION; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; REVIEW; RISK; VASCULARIZATION; VEIN THROMBOSIS;

ARM; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; CATHETERIZATION, CENTRAL VENOUS; HEPARIN; HUMANS; ONTARIO; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 0037905743     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1448     Document Type: Article

References (13)

1. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet. 1982;2:1246-1249.
2. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
3. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
4. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804-812.
5. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96:846-851.
6. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
7. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol. 1997;56:12-16.
8. Elliott G. Upper-extremity deep vein thrombosis. Lancet. 1997;349:1188-1189.
9. Hingorani A, Ascher E, Yorkovich RPA, et al. Upper extremity deep venous thrombosis: an underrecognized manifestation of a hypercoagulable state. Ann Vasc Surg. 2000;14:421-426.
10. Leebeek FWG, Stadhouders NAM, van Stein D, Gómez-Garcfa EB, Kappers-Klunne MC. Hypercoagulability states in upper-extremity deep venous thrombosis. Am J Hematol. 2001;67:15-19.
11. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. 2nd ed. New York, New York: Marcel Dekker, Inc; 2001:43-86.
12. Warkentin TE. Heparin-induced skin lesions. Br J Haematol. 1996;92:494-497.
13. Cook D, Crowther M, Meade M, et al. Deep venous thrombosis in medical-surgical ICU patients: prevalence, incidence and risk factors [abstract]. Crit Care. In press.